VIEWPOINT
Drug-eluting stents for diabetes mellitus
A rush to judgment?
Aloke V. Finn, MD*,*,
Igor F. Palacios, MD*,
Adnan Kastrati, MD and
Herman K. Gold, MD*
* Cardiac Unit, Massachusetts General Hospital, Boston, Massachusetts
Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität München, Munich, Germany
Manuscript received July 25, 2004;
revised manuscript received October 9, 2004,
accepted October 18, 2004.
* Reprint requests and correspondence: Dr. Aloke V. Finn, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114. (Email: afinn1{at}partners.org).
The two pivotal U.S. trials of drug-eluting stents do not establish the principle that these stents are superior to thin-strut bare-metal stents for preventing repeat revascularization in patients with diabetes. Neither study was adequately powered to make this determination. Moreover, both studies used thick-strut stents known to have high restenosis rates as controls. Low angiographic follow-up underestimates the true target lesion revascularization rate in the Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease (TAXUS-IV) trial because of the high incidence of silent ischemia in patients with diabetes. Optimal therapy for diabetic coronary disease should include a comprehensive approach directed toward metabolic normalization in addition to local stent-based therapy.
|
Abbreviations and Acronyms
| | BMS = bare-metal stent | | DES = drug-eluting stents | | ISAR-STEREO = Intracoronary Stenting and Angiographic Results-Strut Thickness Effect on Restenosis Outcomes trial | | PCI = percutaneous coronary intervention | | PES = paclitaxel-eluting stent | | PPAR = peroxisome proliferator-activated receptor | | RVD = reference vessel diameter | | SES = sirolimus-eluting stent | | SIRIUS = Sirolimus-coated BX Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Coronary Artery Lesions | | TAXUS-IV = Polymer-Based Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease | | TLR = target lesion revascularization |
|
This article has been cited by other articles:

|
 |

|
 |
 
J. M. Edwards, Z. P. Neeb, M. A. Alloosh, X. Long, I. N. Bratz, C. R. Peller, J. P. Byrd, S. Kumar, A. G. Obukhov, and M. Sturek
Exercise training decreases store-operated Ca2+entry associated with metabolic syndrome and coronary atherosclerosis
Cardiovasc Res,
October 4, 2009;
(2009)
cvp308v2.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. S. Brar, J. Kim, S. K. Brar, R. Zadegan, M. Ree, I.-L. A. Liu, P. Mansukhani, V. Aharonian, R. Hyett, and A. Y.-J. Shen
Long-term outcomes by clopidogrel duration and stent type in a diabetic population with de novo coronary artery lesions.
J. Am. Coll. Cardiol.,
June 10, 2008;
51(23):
2220 - 2227.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. C Mcmahon, H. Zreiqat, and H. C Lowe
Carotid artery stenting in the Zucker rat: a novel, potentially 'diabetes-specific' model of in-stent restenosis
Diabetes and Vascular Disease Research,
June 1, 2008;
5(2):
145 - 146.
[PDF]
|
 |
|

|
 |

|
 |
 
M. L. Brown, T. M. Sundt III, and B. J. Gersh
Indications for Revascularization
Card. Surg. Adult,
January 1, 2008;
3(2008):
551 - 572.
[Full Text]
|
 |
|

|
 |

|
 |
 
F. Tomai, B. Reimers, L. De Luca, A. R. Galassi, A. Gaspardone, A. S. Ghini, V. Ferrero, L. Favero, G. Gioffre, F. Prati, et al.
Head-to-Head Comparison of Sirolimus- and Paclitaxel-Eluting Stent in the Same Diabetic Patient With Multiple Coronary Artery Lesions: A prospective, randomized, multicenter study
Diabetes Care,
January 1, 2008;
31(1):
15 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-C. Fang, Yeun Tarl Fresner Ng Jao, Yi-Chen, C.-L. Yu, C.-L. Chen, and S.-P. Wang
Angiographic and Clinical Outcomes of Rosiglitazone in Patients With Type 2 Diabetes Mellitus After Percutaneous Coronary Interventions: A Single Center Experience
Angiology,
November 1, 2007;
58(5):
523 - 534.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J. Suppl.,
June 1, 2007;
9(suppl_C):
C3 - C74.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Berry, J.-C. Tardif, and M. G. Bourassa
Coronary Heart Disease in Patients With Diabetes: Part II: Recent Advances in Coronary Revascularization
J. Am. Coll. Cardiol.,
February 13, 2007;
49(6):
643 - 656.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al.
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
Eur. Heart J.,
January 1, 2007;
28(1):
88 - 136.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. B. Barner
Status of percutaneous coronary intervention and coronary artery bypass.
Eur. J. Cardiothorac. Surg.,
September 1, 2006;
30(3):
419 - 424.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Stettler, S Allemann, M Egger, S Windecker, B Meier, and P Diem
Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials
Heart,
May 1, 2006;
92(5):
650 - 657.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. E. Williams
Coronary Revascularization in Diabetic Chronic Kidney Disease/End-Stage Renal Disease: A Nephrologist's Perspective
Clin. J. Am. Soc. Nephrol.,
March 1, 2006;
1(2):
209 - 220.
[Full Text]
[PDF]
|
 |
|
|